HRH3 and depressive symptom measurement: This study demonstrates that pitolisant, an FDA‐approved H3R antagonist, effectively suppresses EtOH‐induced locomotor stimulation and reward, reduces voluntary alcohol consumption, and alleviates withdrawal‐induced anxiety and depression‐like behaviors in mice.